Abstract:Background: Angiotensin II receptor blockers (ARBs) are utilized for the management of hypertension and diabetes. Previous meta-analyses suggested that azilsartan medoxomil (AZL-M) improved blood pressure (BP) reduction, but there were no safety findings or suggestions for patients with hypertension or diabetes. Methods: We performed an efficacy and safety meta-analysis of randomized controlled trials (RCTs) evaluating AZL-M therapy for reducing BP in patients with hypertension. Patients with hypertension complicated by diabetes were analyzed. The relevant literature was searched in English and Chinese databases for RCTs involving AZL-M in hypertension. Efficacy variables included the change from baseline in the 24-h mean systolic/diastolic BP measured by ambulatory BP monitoring, the change from baseline in clinic systolic/diastolic BP, and responder rates. Safety variables included total adverse events (AEs), serious AEs, AEs leading to discontinuation, and AEs related to the study drug. The raw data from the included studies were utilized to calculate the odds ratio (OR) for dichotomous data and the mean difference (MD) for continuous data, accompanied by 95% confidence intervals (CIs). Statistical analysis was performed using R software. Results: A total of 11 RCTs met the inclusion criteria, representing 7,608 patients, 5 of whom had diabetes. Pooled analysis suggested a reduction in BP among patients randomized to 40 mg of AZL-M vs. control therapy [24-h ambulatory blood pressure monitoring (ABPM) mean systolic blood pressure (SBP) (MD: -2.85 mmHg), clinic SBP (MD: -3.48 mmHg), and clinic diastolic blood pressure (DBP) (MD: -1.96 mmHg)] and for 80 mg of AZL-M vs. control therapy [24-h ABPM mean SBP (MD: -3.59 mmHg), 24-h ABPM mean DBP (MD: -2.62 mmHg), clinic SBP (MD: -4.42 mmHg), clinic DBP (MD: -3.09 mmHg), and responder rate (OR: 1.46)]. There was no difference in the reduction of risks, except for dizziness (OR: 1.56) in the 80-mg AZL-M group or urinary tract infection (OR: 1.82) in the 40-mg AZL-M group. Analysis of patients with diabetes revealed that AZL-M can provide superior management, while safety and tolerability were similar to those of control therapy. Conclusions: AZL-M appears to reduce BP to a greater extent than dose-control therapy and does not increase the risk of adverse events in patients with hypertension and diabetes compared with placebo. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=464284, identifier PROSPERO CRD42023464284.

A randomized controlled trial of arotinolol and amlodipine in diabetes patients with hypertension

Clinical Effects of Arotinolol in Patients with Essential Hypertension

Effects of Atenolol and Diltiazem-Sr on Quality of Life in the Hypertensive Patients

Effect and safety of telmisartan and amlodipine in treatment of hypertension complicated with diabetes：a Meta-analysis

Effects of Amlodipine Plus Telmisartan or Amlodipine Plus Amiroride Regimen on Blood Pressure Control in Hypertensive Patients:Preliminary Report of Chinese Hypertension Intervention Efficacy (Chief)trial

A Meta-Analysis of the Efficacy and Safety of Arotinolol in the Treatment of Chinese Patients with Essential Hypertension

Multicenter trial of Arotinolol treatment for chronic renal insufficiency with hypertension

Clinical Trial of Arotinolol in the Treatment of Hypertension: Dippers Vs. Non-Dippers

Efficacy and safety of aranidipine enteric-coated tablets compared with amlodipine in Chinese patients with mild to moderate essential hypertension: a multicenter, randomized, double-blind, parallel-controlled clinical trial.

A5504 Comparison of the Effects of Valsartan and Amlodipine on the Characteristics of Ambulatory Blood Pressure in Hypertensive Patients

The Effectiveness and Safety of L-amlodipine Besylate for Blood Pressure Control in Patients with Mild to Moderate Essential Hypertension

Efficacy and safety of azilsartan medoxomil in the treatment of hypertension: a systematic review and meta-analysis

Effect of combining valsartan and amlodipine in the treatment of type 2 diabetes mellitus complicated by hypertension

Arotinolol for Essential Hypertension

Efficacy and tolerability of initial high vs low doses of S-(-)-amlodipine in hypertension

A clinical trial for evaluating efficacy and safety of amlodipine besylate/atorvastatin calcium in treating hypertension complicated with hyperlipidemia

PS 14-31 AMBULATORY BLOOD PRESSURE LOWERING EFFICACY AND TOLERABILITY OF INITIAL HIGH DOSE OF AMLODIPINE IN MILD OR MODERATE HYPERTENSION

525 4 YEARS OUTCOME OF AMLODIPINE PLUS TELMISARTAN OR AMLODIPINE PLUS DIURETICS REGIMEN ON CARDIOVASCULAR EVENTS IN HYPERTENSIVE PATIENTS 13542

Mata analysis on arotinolol in treatment of essential hypertension

The Efficacy and Safety of Amlodipine Maleate on Patients with Mild to Moderate Essential Hypertension

Efficacy and safety of single-pill amlodipine/losartan versus losartan in patients with inadequately controlled hypertension after losartan treatment: a multicenter, double-blind, randomized phase III clinical trial